Medicines Co's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Medicines Co (MDCO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Medicines Co vs Its Competitors
- TTM: Trailing 12-month revenue of 85M vs 316,726M combined for tracked competitors (0.0% combined share).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Medicines Co vs. its Competitors, Q3 2019
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Medicines Co and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Medicines Co | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Medicines Co's competitor groups requires a Commercial License.
Medicines Co's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Medicines Co | - | - | - | Yes |
| Competitors combined (50) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MDCO Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Gt Biopharma Inc | 282.9% | Outperformed |
| 2 | Moderna Inc | 282.9% | Outperformed |
| 3 | 180 Life Sciences Corp | 282.9% | Outperformed |
| 4 | Immunovant Inc | 282.9% | Outperformed |
| 5 | Xencor Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Medicines Co's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Medicines Co
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Medicines Co | 6,802.95 | 85.03 |
| Merck and Co Inc | 365,683.50 | 66,569.00 |
| Gilead Sciences Inc | 185,927.94 | 30,457.00 |
| Abbott Laboratories | 176,035.08 | 45,134.00 |
| Pfizer Inc | 162,677.96 | 63,696.00 |
| Vertex Pharmaceuticals Inc | 134,619.28 | 12,587.20 |
| SUBTOTAL | 1,460,686.02 | 326,022.34 |
Sign in to see all competitors of Medicines Co.
Sources: Medicines Co's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Medicines Co versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Medicines Co's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Vaxart Inc | Named by the company | 85% |
| C4 Therapeutics Inc | Named by the company | 85% |
| Enveric Biosciences Inc | Named by the company | 85% |
| Keros Therapeutics Inc | Named by the company | 85% |
| Moderna Inc | Named by the company | 85% |
| Alnylam Pharmaceuticals Inc | Named by the company | 85% |
| Petvivo Holdings Inc | Named by the company | 85% |
| Biocardia Inc | Named by the company | 85% |
| Regencell Bioscience Holdings Limited | Named by the company | 85% |
| Vertex Pharmaceuticals Inc | Named by the company | 85% |
| Bristol myers Squibb Company | Named by the company | 85% |
| Zoetis Inc | Named by the company | 85% |
| Editas Medicine Inc | Named by the company | 85% |
| Immunovant Inc | Named by the company | 85% |
| Mira Pharmaceuticals Inc | Named by the company | 85% |
| Abbott Laboratories | Named by the company | 85% |
| Organon and Co | Named by the company | 85% |
| Artelo Biosciences Inc | Named by the company | 85% |
| Pharmacyte Biotech Inc | Named by the company | 85% |
| Telomir Pharmaceuticals Inc | Named by the company | 85% |
| Bullfrog Ai Holdings Inc | Named by the company | 85% |
| Xencor Inc | Named by the company | 85% |
| Calidi Biotherapeutics Inc | Named by the company | 85% |
| Gilead Sciences Inc | Named by the company | 85% |
| Lantern Pharma Inc | Named by the company | 85% |
| Neurocrine Biosciences Inc | Named by the company | 85% |
| Alterola Biotech Inc | Named by the company | 85% |
| Pfizer Inc | Named by the company | 85% |
| Bicycle Therapeutics Plc | Named by the company | 85% |
| Springworks Therapeutics Inc | Named by the company | 85% |
| Viatris Inc | Named by the company | 85% |
| Barinthus Biotherapeutics Plc | Named by the company | 85% |
| Zevra Therapeutics Inc | Named by the company | 85% |
| Elanco Animal Health Incorporated | Named by the company | 85% |
| Inmune Bio Inc | Named by the company | 85% |
| Merck and Co Inc | Named by the company | 85% |
| Agios Pharmaceuticals Inc | Named by the company | 85% |
| Passage Bio Inc | Named by the company | 85% |
| 180 Life Sciences Corp | Named by the company | 85% |
| Prime Medicine Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Medicines Co's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Medicines Co's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Medicines Co | 6,803 | - | - |
| Merck and Co Inc | 365,684 | 887,587 | 42,267 |
| Gilead Sciences Inc | 185,928 | 1,791,588 | -190,588 |
| Abbott Laboratories | 176,035 | 392,470 | 54,574 |
| Pfizer Inc | 162,678 | 849,280 | 58,267 |
| Vertex Pharmaceuticals Inc | 134,619 | 31,079,506 | 10,877,037 |
| PEERS TOTAL | 1,453,883 | 792,060 | 50,853 |
Medicines Co's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 70.78 % |
| Abbott Laboratories | Non-US 61.62 % |
| Pfizer Inc | United States 58.91 % |
| Vertex Pharmaceuticals Inc | United States 61.68 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Medicines Co's Business Segment Mix vs Peers
Revenue by operating segment, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Abbott Laboratories | Diabetes Care 17.78 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Zoetis Inc | International 50.80 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Medicines Co's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | -123.4x | 4.5x | -127.9x |
| Return on Equity | 794.15 % | industry aggregate | 782.09 % |
| Return on Invested Capital | -25.55 % | -2.95 % (avg) | -22.60 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Medicines Co's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2013 | 2014 | 2015 | 2017 | 2018 |
|---|---|---|---|---|---|
| Revenue Growth | 23.14 % | 5.31 % | -57.34 % | -57.25 % | - |
| Operating Margin | 1.92 % | -8.91 % | -88.18 % | -972.02 % | - |
| Return on Invested Capital | 0.75 % | -2.57 % | -10.65 % | -64.15 % | -26.03 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Medicines Co's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) — not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 782.1 points above the industry aggregate.
Weaknesses
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (38.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-37.4% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Medicines Co's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Medicines Co | 1.68 | 2.07 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Abbott Laboratories | 0.47 | 1.60 | 0.35 |
| Pfizer Inc | 0.04 | 1.24 | 0.71 |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Medicines Co's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Medicines Co | Q3 2019 | - | - |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Abbott Laboratories | Q1 2026 | +7.8 % | -18.7 % |
| Pfizer Inc | Q2 2026 | +2.6 % | - |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| PEERS TOTAL | +6.7 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Medicines Co's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Medicines Co | Q3 2019 | - | - |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Abbott Laboratories | Q1 2026 | +9.4 % | -17.6 % |
| Pfizer Inc | Q2 2026 | +8.3 % | -13.8 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
Medicines Co's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Medicines Co | - | - | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Gilead Sciences Inc | - | - | - |
| Abbott Laboratories | 6.87% | 8.15% | 12.09% |
| Pfizer Inc | 2.12% | 2.53% | 4.91% |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Medicines Co's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Medicines Co | - | 80.01 |
| Merck and Co Inc | 119.40 | 5.49 |
| Gilead Sciences Inc | - | 6.10 |
| Abbott Laboratories | 28.07 | 3.90 |
| Pfizer Inc | 37.43 | 2.55 |
| Vertex Pharmaceuticals Inc | 30.76 | 10.69 |
| PEERS AVERAGE | 70.60 | 4.48 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.